Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Clinical trial NCT06561152 · RECRUITING

Trial details

NCT number: NCT06561152
Sponsor: Stanford University
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Acute Myeloid Leukemia Relapsed Acute Myeloid Leukemia

Start date: 2025-02-10
Primary completion: 2027-10-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.